(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 September 2012 (20.09.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/125864 A2

(51) International Patent Classification:
A61K 39/395 (2006.01) *A61K 33/00* (2006.01)
A61K 31/00 (2006.01) *C07K 16/32* (2006.01)

(21) International Application Number:
PCT/US2012/029292

(22) International Filing Date:
15 March 2012 (15.03.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/452,976 15 March 2011 (15.03.2011) US
61/452,974 15 March 2011 (15.03.2011) US

(71) Applicant *(for all designated States except US)*: **MERRIMACK PHARMACEUTICALS, INC.** [US/US]; One Kendall Square, Suite B7201, Cambridge, MA 02139 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **GARCIA, Gabriela** [BR/US]; 14 Knoll St., Roslindale, MA 02131 (US). **KUBASEK, William** [US/US]; 165 Fairview Ave., Belmont, MA 02478 (US). **LAHDENRANTA, Maria, Johanna** [FI/US]; 29 Wendell St., #2, Cambridge, MA 02138 (US). **MACBEATH, Gavin** [US/US]; 4222 Kirkbride Drive, Danvers, MA 01923 (US). **MCDONAGH, Charlotte** [GB/US]; 11 Sargent Road, Winchester, MA 01890 (US). **MOYO, Victor** [ZW/US]; 1694 Main Street, Apt. #5, Concord, MA 01742 (US). **ONSUM, Matthew, David** [US/US]; 90 Bynner Street, Jamaica Plain, MA 02130 (US). **SEVECKA, Mark** [DE/US]; 333 Pearl St., Cambridge, MA 02139 (US). **WAINSZELBAUM, Marisa** [AR/US]; 1 Emerson Pl, Apt. 12h, Boston, MA 02114 (US). **ZHANG, Bo** [CN/US]; 14 Village Row, Lynnfield, MA 01940 (US).

(74) Agents: **REMILLARD, Jane, E.** et al.; Nelson Mullins Riley & Scarborough Llp, One Post Office Square, Boston, MA 02109-2127 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

WO 2012/125864 A2

(54) **Title**: OVERCOMING RESISTANCE TO ERBB PATHWAY INHIBITORS

(57) **Abstract**: Provided are methods for overcoming resistance to an ErbB pathway inhibitor, such as an EGFR inhibitor or a HER2 inhibitor. The resistance may be acquired resistance to an EGFR inhibitor, such as acquired resistance to gefitinib. In the methods provided, a subject exhibiting resistance to an ErbB pathway inhibitor is selected and both an ErbB 3 inhibitor and a second ErbB pathway inhibitor are administered to the subject, such as an EGFR inhibitor or a HER2 inhibitor. Also provided are methods for inhibiting the growth of a tumor comprising a T790M EGFR mutation by contacting the tumor with an ErbB3 inhibitor and an EGFR inhibitor. Compositions for overcoming resistance to an ErbB pathway inhibitor, comprising both an ErbB 3 inhibitor and a second ErbB pathway inhibitor, such as an EGFR inhibitor or a HER2 inhibitor, are also provided.